Exact Sciences Corporation (EXAS) & Its Rivals Financial Comparison
Exact Sciences Corporation (NASDAQ: EXAS) is one of 199 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare Exact Sciences Corporation to similar companies based on the strength of its earnings, analyst recommendations, dividends, valuation, institutional ownership, risk and profitability.
Earnings & Valuation
This table compares Exact Sciences Corporation and its rivals revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Exact Sciences Corporation||$169.37 million||-$129.74 million||-47.41|
|Exact Sciences Corporation Competitors||$206.18 million||-$2.14 million||2.50|
Exact Sciences Corporation’s rivals have higher revenue and earnings than Exact Sciences Corporation. Exact Sciences Corporation is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
85.1% of Exact Sciences Corporation shares are held by institutional investors. Comparatively, 46.9% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 4.0% of Exact Sciences Corporation shares are held by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares Exact Sciences Corporation and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Exact Sciences Corporation||-60.71%||-30.32%||-27.37%|
|Exact Sciences Corporation Competitors||-3,961.77%||-118.02%||-43.71%|
Volatility and Risk
Exact Sciences Corporation has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Exact Sciences Corporation’s rivals have a beta of 1.62, suggesting that their average stock price is 62% more volatile than the S&P 500.
This is a summary of current recommendations for Exact Sciences Corporation and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Exact Sciences Corporation||0||4||9||0||2.69|
|Exact Sciences Corporation Competitors||483||2288||6249||120||2.66|
Exact Sciences Corporation presently has a consensus price target of $50.46, suggesting a potential downside of 8.24%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.87%. Given Exact Sciences Corporation’s rivals higher possible upside, analysts clearly believe Exact Sciences Corporation has less favorable growth aspects than its rivals.
About Exact Sciences Corporation
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.